NC
AURA icon

nVerses Capital’s Aura Biosciences AURA Stock Holding History

nVerses Capital’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-400
Closed -$3.56K – 87
2024
Q3 		$3.56K Buy
+400
New +$3.43K ﹤0.01% 944

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

nVerses Capital's AURA Position: Q4 2024 in Review

nVerses Capital sold out of Aura Biosciences (AURA) in Q4 2024, closing a stake of 400 shares — an estimated $3.56K sold.

nVerses Capital first reported a position in AURA in Q3 2024 and held it in 1 quarter. The position peaked at $3.56K in Q3 2024. 94 funds tracked by Wall St. Rank hold AURA as of Q4 2024.

  • nVerses Capital reported no remaining Aura Biosciences position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 400 Aura Biosciences shares in Q4 2024, an estimated $3.56K.
  • nVerses Capital first reported a position in Aura Biosciences in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's Aura Biosciences position peaked at $3.56K in Q3 2024.
  • 94 funds tracked by Wall St. Rank held Aura Biosciences as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.